A valve-in-valve procedure for dysfunctional bioprosthetic mitral valves had lower 1-year risk for death and stroke than redo ...

("VDYNE" or "the Company"), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Administration ...

The first RCT to compare valve-in-valve vs redo surgery reassures, especially for regions where rheumatic valve disease is prevalent.

Solo Pace Incorporated, an emerging medical technology company, today announced the commercial release of the SoloPace FUSION(TM) Temporary Pacing System. The launch follows US Food and Drug ...

In the first head-to-head comparison of two devices intended to protect against stroke in patients undergoing transcatheter ...

The Trilogy THV System is the first and only transcatheter device in the United States with a dedicated indication for high-risk aortic regurgitation (AR) - a historically underserved and ...

In patients with a poorly functioning bioprosthetic mitral valve in the heart, a minimally invasive procedure to insert a new valve was associated with a lower rate of death or disabling stroke within ...

This marks the first dedicated transcatheter heart valve approved for high-risk patients with symptomatic severe AR.

Older patients with coronary artery disease scheduled for transcatheter aortic valve replacement (TAVR) had comparable ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

A medical milestone was achieved in Greece with the country’s first heart TAVI-in-TAVI procedure to treat a degenerated ...